Researchers sought to assess the prevalence of concomitant prescribing of opioid analgesics with a triptan or a serotogeneric antidepressant in individuals with migraine.
Investigators examined rates, predictors, and outcomes of neuroimaging in pediatric and adolescent patients who presented to the ED with a headache.
Patients with migraine headaches—particularly those accompanied by aura—may be at significantly increased risk for 30-day hospital readmission because of pain after surgery.
Investigators assessed the effect of erenumab on total exercise time, time to exercise-induced angina, and ST depression in patients with stable angina.
No significant clinical differences have been found between individuals with cluster headache who experience aura vs no aura.
People with migraines and comorbid mood disorders often need treatments that address both conditions, as well as management of sleep, stress, and lifestyle issues.
Investigators examined the effect of onabotulinumtoxinA on aura frequency and severity in patients with hemiplegic migraine.
The location of migraine pain may not be associated with psychiatric distress, emergency department visits, or healthcare use.
Investigators examined the efficacy of oral steroids and greater occipital nerve injections as transitional therapies for cluster headache management.
Carefully assessing cognitive performance using a screening test to detect visuospatial/executive, attention, and memory dysfunction in patients with migraine.
Known risk factors for medication overuse headache include smoking, anxiety, family history of substance abuse, migraine history, depression, and obsessive-compulsive disorder.
Two-thirds of parents report that their child has had a headache not related to a fall or head injury.
The comorbidities commonly reported in patients with migraine include those involving cardiovascular, psychiatric, pain, and respiratory conditions, the researchers reported.
This Phase III, multicenter, double-blind study sought to explore the effect of fremanezumab on the potential reversion from chronic migraine to episodic migraine.
Men with migraines were found to have increased levels of estradiol and to be more likely to have relative androgen deficiency compared with men without migraines.
Patients with difficult-to-treat migraine were randomly assigned 1:1 to either 140 mg erenumab or placebo.
Acute confusional migraine has not been specifically studied and many clinicians remain unaware of the condition, which may result in underestimation of the prevalence.
Approximately half of patients who were referred for behavioral treatment for migraine were found to initiate treatment.
A phase 3 study examined a low-dose subcutaneous autoinjection of sumatriptan in the acute treatment of migraines with or without aura in adults.
Dr Richard Lipton and Dr Paul Martin debated the pros and cons of trigger avoidance in patients with migraine headache at the 2018 American Headache Society Annual Scientific Meeting in San Francisco, California.
The risk for cochlear disorders — particularly tinnitus — may be higher in individuals with a history of migraine.
Current oral contraceptive products contain lower doses of estrogen than those used in the past, prompting reconsideration of risks and benefits.
The 2 randomized, phase 3, double-blind studies included in this presentation were the SAMURAI and SPARTAN trials.
Individuals with chronic migraine may present with age-related changes in cortical thickness.
Color-selective photophobia was found to be more prevalent during the ictal vs interictal phase in individuals with migraine.
The treatment may be beneficial in patients whose acute migraine does not respond to standard treatment with intravenous metoclopramide.
Eptinezumab has shown 100% bioavailability when administered intravenously.
This cross-sectional, observational study sought to evaluate the accuracy of individuals with headache to appraise the relationship between potential trigger factors and headache events.
More patients in the 100 mg and 300 mg eptinezumab groups achieved a 100% reduction in monthly migraine days over the 112 weeks compared with placebo.
This retrospective study sought to assess migraine patterns in 69 menopausal women between ages 40 and 60 who were treated at Partners Healthcare Hospitals for concurrent migraine headache.
Clinical Pain Advisor Articles
- Opioid Use Disorders: Advances in Pharmacotherapy Provide Long-term Results
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Prioritizing Rest in Hospital Settings: Poor Sleep Increases Costs, Complications, and Mortality
- Pain Catastrophizing Decreases in Rheumatoid Arthritis After DMARD Initiation
- Addressing Commercial Incentives in the Medical Device Industry
- Cancer Patients Treated With Step III Opioids Often Have Sleep Disturbances
- Low Literacy Self-Management Program for Chronic Pain May Be Effective